October 2025 - Page 8 of 10

WednesdayOct 08, 2025 12:00 pm

OptimumBank Holdings Inc. (NYSE American: OPHC) Posts $3.6M Q2 Earnings, Surpasses $1bn in Assets, Will Showcase Achievements at National Conferences

OptimumBank’s Q2 2025 earnings reached $3.6 million, with deposits growing at a double-digit annualized pace. The Bank now proudly exceeds $1 billion in total assets. Chairman Moishe Gubin to present third-quarter highlights at the LD Micro Main Event XIX in San Diego, October 19-21. OptimumBank will sponsor and attend the Jewish National Fund Global Conference in Hollywood, Florida, October 23-26. The Bank recently sponsored the 2025 Brokers Expo in New York, underscoring outreach to small businesses. OptimumBank Holdings (NYSE American: OPHC), a bank holding company that owns 100% of community bank OptimumBank, headquartered in Fort Lauderdale, Florida, is stepping onto…

WednesdayOct 08, 2025 11:15 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Izotropic Corp. marks a significant milestone in breast imaging with its patent-pending personalized radiation dose feature with the IzoView Breast CT system Recently, the company secured a $375,000 non-brokered private placement to help with core operations in addition to engaging new PR partners for improved investor communications With projections for global breast imaging expected to hit $8.69 billion by 2030, the company is poised to strategically dominate the market Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently…

WednesdayOct 08, 2025 10:30 am

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients Oncotelic Therapeutics (OTCQB: OTLC) is…

WednesdayOct 08, 2025 9:45 am

Newton Golf Company (NASDAQ: NWTG) Meets High Standards in Golf Equipment Quality

Investing in quality golf equipment can have a profound impact on a player’s game. Newton Golf’s quality product offerings include innovations such as the Fast Motion Driver Shaft and the Newton’s Gravity Putters. Players who select thoughtfully designed, technologically advanced clubs gain measurable improvements in performance, confidence and enjoyment. For golfers aiming to elevate their performance, the equipment they choose can make all the difference. Newton Golf Company (NASDAQ: NWTG) is at the forefront of this philosophy, offering precision-engineered clubs and accessories designed to help players achieve consistency, power and control. The company’s dedication to innovation and quality has established…

WednesdayOct 08, 2025 9:00 am

Numa Numa Resources Inc. Is ‘One to Watch’

This article has been disseminated on behalf of Numa Numa Resources and may include paid advertising. Numa Numa has agreements with the landowners to develop the Panguna Mine, which contains an estimated $100 billion in copper and gold reserves based on current market prices. The company’s business plan supports, but does not depend on, Bougainville’s independence. A diverse set of projects in mining, lime production, and energy infrastructure positions the company for multi-stream revenue generation. Numa Numa’s leadership has extensive experience in Bougainville, the development of large-scale infrastructure ventures in remote locations, and worldwide capital markets. Global economic trends affecting the…

WednesdayOct 08, 2025 9:00 am

As Investors Look for Safety, Gold Producers with Cash Flow Are Emerging as the Market’s Next Leaders

NetworkNewsWire Editorial Coverage: The economic narrative today goes beyond the simple fact that gold prices are climbing. It is also about a weakening U.S. dollar, easing real rates and a global push toward scarce, nonsovereign assets. Spot gold continues to reach new peaks, most recently trading more than $3,800 per ounce, as markets anticipate further Federal Reserve cuts alongside dollar softness. Silver has also surged, marking its highest point in some 14 years. Central banks remain steady buyers, having accumulated record volumes of gold since 2022, reinforcing the wider dedollarization trend. Against this backdrop, mining equities present an increasingly attractive…

TuesdayOct 07, 2025 11:15 am

PowerBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Collaborates with Intellistake Technologies Corp. as a Closed Beta Partner to Test IntelliScope AI Agents

This article has been disseminated on behalf of PowerBank and may include paid advertising. Intellistake Technologies Corporation recently announced PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) as an enterprise beta partner, to help with the company’s continued development of the IntelliScope AI suite. The partnership involves PowerBank providing long-term testing and feedback to help refine IntelliScope’s first enterprise-facing AI agents. The close technical relationship is important for both companies and gives PowerBank an inside track on the use of AI tools focused on the energy industry. Disseminated on behalf of PowerBank Corporation Recently, Intellistake Technologies Corporation, a tech company…

TuesdayOct 07, 2025 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems. The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway. Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results…

TuesdayOct 07, 2025 9:45 am

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Pursues PEA for Drilling, Milling Project to Advance Gold Operation

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising. LaFleur Minerals is ramping up expectations for its gold exploration and processing operation in Quebec, working to restart its wholly-owned mill while completing an assessment of hole-drilling work across its 18,304-hectare (45,230-acre) project The company’s Swanson Gold Deposit site is part of the Abitibi Greenstone Belt, which is a globally renowned gold district LaFleur anticipates its Beacon Gold Mill will deliver near-term revenues from processing custom raw ore projects for neighboring gold claims, while also being available for production of its own gold product once exploration gets…

TuesdayOct 07, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision enables re-filing of an Abbreviated New Drug Application (“ANDA”) for the company’s KETAFREE(TM) product, which the company has now done. Current ketamine formulations use multidose vials with a toxic preservative, Benzethonium Chloride. U.S. ketamine market is estimated at $750 million annually, presenting a significant commercial opportunity. NRx is also advancing NRX-100 and NRX-101 for suicidal depression and PTSD, both with FDA designations. The move aligns with U.S. policy goals on reshoring drug production and reducing toxic additives. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company,…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: October 2025